Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 14, 2022
Share
Sunmax Biotechnology Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 322.73 million compared to TWD 234.81 million a year ago. Revenue was TWD 321.95 million compared to TWD 234.74 million a year ago. Net income was TWD 139.01 million compared to TWD 44.52 million a year ago. Basic earnings per share from continuing operations was TWD 2.55 compared to TWD 0.81 a year ago. Diluted earnings per share from continuing operations was TWD 2.55 compared to TWD 0.81 a year ago. Basic earnings per share was TWD 2.55 compared to TWD 0.81 a year ago. Diluted earnings per share was TWD 2.55 compared to TWD 0.81 a year ago.
For the six months, sales was TWD 647.5 million compared to TWD 501.87 million a year ago. Revenue was TWD 646.71 million compared to TWD 501.78 million a year ago. Net income was TWD 271.97 million compared to TWD 107.46 million a year ago. Basic earnings per share from continuing operations was TWD 4.99 compared to TWD 1.97 a year ago. Diluted earnings per share from continuing operations was TWD 4.99 compared to TWD 1.97 a year ago. Basic earnings per share was TWD 4.99 compared to TWD 1.97 a year ago. Diluted earnings per share was TWD 4.99 compared to TWD 1.97 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.